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Abstract  
RNA binding proteins (RBPs) regulate fundamental processes such as differentiation and 
self-renewal by enabling the dynamic control of protein abundance or isoforms, or through 
the regulation of non-coding RNA.  RBPs are increasingly appreciated as being essential 
for normal hematopoiesis and they are understood to play fundamental roles in 
hematological malignancies by acting as oncogenes or tumor suppressors. Alternative 
splicing has been shown to play roles in the development of specific hematopoietic 
lineages and sequence specific mutations in RBPs lead to dysregulated splicing in myeloid 
and lymphoid leukemias.  RBPs that regulate translation contribute to the development 
and function of hematological lineages, act as nodes for the action of multiple signaling 
pathways and contribute to hematological malignancies. These insights broaden our 
mechanistic understanding of the molecular regulation of hematopoiesis and offer 
opportunities to develop disease biomarkers and new therapeutic modalities. 
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Introduction 
RNA may code for protein (mRNA), but also performs additional functions exemplified by 
ribosomal RNA, microRNA, tRNA and lncRNAs. The biogenesis, fate and function of these 
molecules is directed by dynamic interactions with RNA binding proteins (RBPs). Over 
1,500 proteins have been annotated as RBPs, based upon either the presence of 
characteristic RNA binding domains or their residence within established ribonuclear 
protein complexes1.  Experimental approaches employing U.V.-crosslinking of RNA to 
protein followed by selection of polyadenylated RNAs and analysis of bound proteins by 
mass spectroscopy revealed that many RBPs lacked any conventional RNA binding 
domain and had no previous connection to RNA biology2-4.  Amongst these unexpected 
RBPs was an enrichment for metabolic enzymes. The exact nature and functional 
consequences of many of these interactions remains unclear.  A general assumption is 
that RBPs regulate the fate of the bound mRNA, however, in some instances the mRNA 
may regulate the protein.   
 
More than 40 RNA binding domains have been described. Although each recognizes 
relatively common minimal elements specificity is enhanced by the combinatorial use of 
multiple domains. Regulatory cis-elements, bound by RBPs are typically located within 5’ 
or 3’ untranslated regions (UTRs).  These elements can be extremely diverse and may 
include short sequence motifs, simple hairpin-like structural elements, or highly complex 
folded structures.  RBPs regulate mRNA 5’ capping, splicing, polyadenylation, nuclear 
export, localization, translation, silencing and decay, thereby generating diversity in the 
expressed transcriptome and proteome. The ability of RBPs to be controlled by post-
translational modifications affords a mechanism whereby the cellular transcriptome and 
proteome can be rapidly remodeled. A single RBP may regulate a cohort of transcripts that 
affect a common process, a so-called RNA regulon 5,6.  The use of next generation 
sequencing technologies has increasingly highlighted the importance of RBPs, and their 
roles in splicing and translation, in the pathogenesis of specific hematological 
malignancies.  In this review we focus on how RBPs regulate mRNA, emphasizing their 
role in hematopoiesis and hematological malignancy, and the implications for potential 
therapy. 
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Splicing 
Almost all mRNAs are transcribed as a pre-mRNA containing introns that are excised by a 
multiprotein complex known as the spliceosome (Figure 1A).  Most human genes give rise 
to alternatively spliced transcripts 7,8 and these isoforms may show cell type specificity. 
Alternative splicing may affect the proteome qualitatively by generating variant protein 
isoforms from the same gene. It may also regulate the quantity and timing of protein 
expression, through intron retention, which has emerged from studies of granulopoiesis 
and erythropoiesis as a common and developmentally regulated mechanism of gene 
expression9,10. Whilst some retained introns may promote nuclear transcript decay or 
nonsense mediated decay (NMD), others result in nuclear retention and resistance to 
NMD with subsequent splicing and protein expression delayed until a later developmental 
stage11,12. 
 
Splicing isoform usage is regulated in a tissue, developmental stage and stimulus specific 
manner, often by post-translational modification of RBPs. An example is the RBP 
hnRNPA1; amongst its many contributions to RNA metabolism13 hnRNPA1 controls 
splicing of transcripts required for hematopoiesis.  HnRNPA1 is in turn regulated by the 
ubiquitin ligase TRAF6 downstream of TLR signaling14. Enforced TRAF6 ubiquitination of 
hnRNPA1 in mouse HSPCs led to aberrant splicing and bone marrow failure. This link 
between TLR signaling, splicing and bone marrow failure is of particular interest because 
of the relationship between chronic inflammation and disorders such as myelodysplasia15. 
There is considerable evidence that alternative splicing plays an important role in the 
pathogenesis of myelodysplasia and other hematological malignancies.  Missense 
mutations in splicing factors are found in over 50% MDS16-18.  They are also commonly 
identified in clonal hematopoiesis19,20 and CLL21,22.  Although the spliceosome includes 
more than 200 individual proteins, recurrent mutations are restricted to SRSF2, SF3B1, 
U2AF1 and ZRSR2.  Interestingly, these mutations are always hemizygous, missense 
mutations and are mutually exclusive. The apparent requirement to retain one wildtype 
allele might be therapeutically exploitable and mouse models of splice factor mutation 
leukemia suggest an increased sensitivity to inhibitors of the spliceosome23. 
 
SRSF2 is a splicing factor that promotes exon recognition by the binding of its RNA 
recognition motif to exonic splicing enhancer sequences in pre-mRNA to recruit further 
components of the spliceosome.  SRSF2 is mutated in over 20% MDS and 50% CMML, 
with P95H being the commonest mutation.  A heterozygous mouse model of the Srsf2 
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P95H mutation developed an expanded hematopoietic progenitor compartment with 
increased proliferation, apoptosis and peripheral blood cytopenias reminiscent of human 
MDS24. In contrast, hematopoietic failure was seen after either homozygous deletion or 
monoallelic expression of mutant Srsf2 confirming the requirement to retain one WT allele 
23,24
. Mutation of P95 changed the RNA binding preference of SRSF2 in mouse and 
human cells resulting in an altered pattern of splicing that partially overlapped between 
studies and species24-29. Ezh2 was identified as an aberrantly spliced transcript that was 
degraded by NMD, thereby reducing protein expression24 (Figure 1B). Furthermore, the 
hematopoietic phenotype was partially reversed by forced expression of Ezh224. However, 
aberrant splicing of Ezh2 could not be detected in two subsequent Srsf2 P95 mutant 
mouse models27,29,30. Attempts to characterize the alternatively spliced transcriptome in 
human patients have included a comprehensive analysis of purified CD34+ HSPCs from 
patients with splicing factor mutant myelodysplasia. This identified many aberrant splicing 
events, with different mechanisms of altered splicing seen with each mutant splice factor.  
Although little overlap was observed at the individual gene level there was convergence 
onto common pathways26.  
  
The splicing factor SF3B1 is part of the U2 snRNP that binds to the branchpoint sequence.  
The K700E mutation is common in both MDS and CLL.  Transcriptomic analysis of CLL 
patients has identified multiple programs dysregulated in the presence of the mutation31 
but whether this is the mechanism by which mutant SF3B1 contributes to CLL 
pathogenesis remains uncertain. Conditional knock-in of this mutation in mouse 
hematopoietic stem cells resulted in anemia and reproduces the broad picture of splicing 
alteration seen in human mutant myelodysplasia32.  However, the abnormally spliced 
transcripts showed almost no overlap between human and mouse, presumably due to the 
limited inter-species conservation of intronic sequences. The fact that phenotypes of 
abnormal hematopoiesis can be reproduced across mouse models of different mutant 
splicing factors, despite the limited overlap in the transcripts altered between human and 
mouse, suggests that it may be the global rather than gene-specific alteration in splicing 
that contributes to pathogenesis. Recently, more general effects of aberrant splicing 
including R-loop formation and induction of the DNA damage response have been 
suggested as contributory mechanisms33.    
 
Spliceosome function may be altered even in the absence of mutations in its protein 
constituents.  Proteomic analysis showed increased expression of spliceosome 
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components in CLL compared to normal B cells, even in the absence of splicing factor 
mutation, suggesting the fundamental importance of splicing in CLL34.  Consistent with the 
possibility of a generalized splicing defect, exposure to the SF3B1 inhibitor spliceostatin A 
induced apoptosis of CLL, but not normal B cells, independent of SF3B1 mutation status 
35
. SF3B1 inhibition with the drug E7107 synergized with, and was able to overcome 
resistance to, the BCL2 inhibitor venetoclax in the TCL1 mouse model of CLL and in 
human CLL cells36. This effect was potentially due to splicing changes in BCL2 family 
genes, in particular MCL1. Importantly, efficacy did not require the presence of splice 
factor mutations, consistent with aberrant splicing as a generalized feature of CLL. These 
results are especially exciting because E7107 has already entered clinical trials for 
patients with solid organ malignancies. However, although effects on splicing of predicted 
target genes were confirmed at the administered doses, the development of unexpected 
optic neuritis and visual loss, led to study discontinuation on safety grounds37,38. This 
toxicity, which had not been predicted from animal studies, emphasizes the need for a 
deeper understanding of the mechanism of action of these drugs and their target RBPs 
before these agents can be optimally deployed in humans. 
 
Mutations may also be found in cis-regulatory elements that recruit the RBPs that regulate 
splicing.  An example in CLL is NOTCH1 where mutation of a cryptic splice site that 
generates a hyper-stable form of NOTCH139.  Similar mutations may have been dismissed 
as silent mutations or may be located in non-coding regions; as such their significance 
may be underappreciated. Altered splicing may contribute to resistance to therapies.  For 
example, loss of CD19 expression during CAR-T therapy in ALL is caused by altered 
expression of the RBP SRSF3 and consequent altered splicing of CD19 mRNA40. New 
technologies for the qualitative analysis of RNA, including novel isoform identification, will 
facilitate a greater understanding of mRNA splicing control in normal and malignant 
hematopoiesis.  
 
Polyadenylation 
Qualitative changes in the transcriptome are also generated by alternative polyadenylation 
(APA).  Most eukaryotic genes contain more than one polyadenylation signal sequence 
and therefore have the potential to express alternative 3’UTRs41.  Early observations 
described how cancer was broadly associated with APA and a global shortening of 3’UTRs 
consistent with a generalized escape from post-transcriptional regulation42.  The selection 
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of polyadenylation sites is influenced in a dynamic fashion by RBPs with approximately 20 
core proteins acting in complexes such as the Cleavage and Polyadenylation Specific 
Factor (CPSF), cleavage factor-1 and -2 (CFI and CFII), poly(A) polymerase and poly(A) 
binding proteins43.   
 
APA may also occur at polyadenylation signals within intronic regions of the transcript.  
This can lead to exclusion of coding regions and the generation of truncated proteins with 
lost or altered function.  Recent studies show that intronic polyadenylation is commonplace 
both in normal and malignant cells with differential intronic polyadenylation associated with 
progression of B cell development44.  Furthermore, analysis of CLL identified widespread 
intronic polyadenylation resulting in truncation of transcripts encoding potential tumor 
suppressors45.  Indeed, inactivation of potential tumor suppressors by intronic 
polyadenylation was more common than inactivation by DNA mutation. Altered transcripts 
included genes annotated as tumor suppressors in other malignancies but not previously 
recognized as being altered at the DNA level in CLL. Since APA will not be detected by 
genomic DNA sequencing this suggests the existence of a dominant mechanism of tumor 
suppression that has yet to be fully explored. How the expression, mutation and 
modification of RBPs contribute to the selection of APA sites during hematopoiesis and 
leukemogenesis is an exciting area of ongoing research.   
 
APA may affect gene expression by several mechanisms. An obvious assumption is that 
shortening of the 3’UTR leads to the loss of cis-regulatory elements that determine binding 
of RBPs and microRNAs, in turn leads to altered expression of that transcript.  An 
intriguing further possibility arises from the suggestion that some transcripts act as 
sponges to sequester RBPs or microRNAs that would otherwise regulate the expression of 
additional transcripts, thereby acting as “competing endogenous RNAs” (ceRNAs). A 
recent model-based analysis suggests that the regulation of many tumor suppressor 
transcripts is influenced by the APA and loss of regulatory elements in other ceRNA 
transcripts46. This emphasizes the complexity of the networks of post-transcriptional 
regulation that are coordinated by RBPs. 
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Translation   
The rate of translation is tightly controlled in normal hematopoiesis47 and commonly 
dysregulated in cancers including hematological malignancies. Regulation of translation 
can occur during the initiation, elongation and termination phases however, initiation is 
often the rate limiting step. Binding of the mRNA 5’cap by EIF4E is required for translation 
of most mRNAs. EIF4E forms part of the EIF4F complex with EIF4G and EIF4A. EIF4G 
acts as scaffold by binding to the 40S ribosome-containing pre-initiation complex. EIF4A is 
a DEAD box containing helicase that unwinds structural elements in the 5’UTR as the pre-
initiation complex scans along 5’UTR until the 60S ribosome is recruited at a suitable start 
codon and protein synthesis is initiated. 
 
EIF4E overexpression is commonly seen in human cancer and its forced expression can 
be transforming in vitro48,49.  In vivo experiments revealed that overexpression of EIF4E in 
transgenic mice led to the development of multiple cancer types including B cell 
lymphomas50 and accelerated lymphomagenesis in a c-myc mouse model51. The 
transforming effect of EIF4E was not due to the global increase in protein synthesis but 
rather to a previously recognized selectivity for transcripts related to proliferation, survival 
and metabolism49. Further evidence of this oncogenic specificity came from Eif4e+/- mice 
in which 50% expression of EIF4E was sufficient for normal levels of global translation, 
and normal development, but insufficient to permit HRAS-induced cellular 
transformation52. This was due to reduced translation of a “regulon” of transcripts required 
for cellular transformation. Enhanced EIF4E binding to these transcripts was mediated by 
a C-rich motif in the 5’UTR. The existence of this differential requirement for EIF4E 
expression suggests the existence of a therapeutic window that might be exploited to 
suppress tumor growth.   In addition to its role in translation initiation EIF4E may also play 
a separate role in the selective export of oncogenic mRNAs from the nucleus.  Indeed, this 
activity has been successfully targeted in clinical trials of AML using the m7G-cap 
analogue ribavirin53.  The selectivity of EIF4E in promoting both the nuclear export and 
translation of MYC, BCL2 and BCL6, has been proposed as a therapeutic strategy to 
target double and triple hit DLBCL54. 
 
Another potential therapeutic target is the RNA helicase EIF4A. Exposure of leukemic cells 
to the EIF4A inhibitor silvestrol leads to translational downregulation of a program of G-
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quadruplex containing transcripts enriched for oncogenes and showed significant activity 
against leukemic cell lines55. Activity of EIF4A is positively regulated by EIF4B, a protein 
that is overexpressed in diffuse large B cell lymphoma56.  Increased EIF4B promotes 
translation of an oncogenic regulon that includes anti-apoptotic and DNA repair proteins. 
RNA helicases represent a promising target for anticancer drug development, especially 
as many such inhibitors are already in development as anti-viral agents. 
 
In addition to canonical cap-dependent translation facilitated by EIF4E it is clear that other 
proteins may also act as cap-binders. The multi-subunit eIF3 complex acts as a bridge 
between the 40S ribosome and EIF4G. However, subunit EIF3D is responsible for m7G 
cap recruitment in many mRNAs and may allow ongoing translation in the absence of 
EIF4E or during mTOR inhibition. Indeed, EIF3 appears to regulate the translation of 
specialized mRNA regulons involved in proliferation and apoptosis57.  This specificity 
relates to structural elements within the 5’UTR of specific mRNAs that  permit EIF3d m7G 
cap binding58.  Knock down of EIF3D inhibits cell proliferation in a number of different 
cancer cell lines including AML59.  
 
The activity of these protein complexes and thus initiation is regulated by signaling 
pathways (Figure 2). The best characterized of these is mTORC1 which phosphorylates 
and inactivates eIF4E-BP to release the cap binding activity of EIF4E. mTORC1 can also 
induce the degradation of PDCD4, a negative regulator of EIF4A, through phosphorylation 
via S6 kinase. In CD4 T cells engagement of the T cell receptor triggers rapid mTOR 
activation and alters metabolism through the translation of a program of pre-existing or 
“poised” mRNAs 60. Translation is also regulated by the B cell receptor.  In CLL 
engagement of the BCR is shown to enhance both global translation and the specific 
translational upregulation of MYC61. Increased MYC promotes expression of the 
translational machinery increasing ribosome production and activity. These changes 
appeared to depend upon enhanced expression of eIF4A and eIF4G and a reduction of 
PDCD4. The role of BCR signaling as a tractable therapeutic target to influence 
downstream RBP activity was supported by the ability of inhibitors of BCR kinases SYK 
and BTK to fully or partially reverse the effects on translation. 
   
Further specificity of the translation initiation step is added by a number of mechanisms.  
The 5’UTRs of mRNAs encoding oncogenes may differ in length, structure, or specific 
sequence motifs, rendering them more sensitive to changes in the abundance or activity of 
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RBPs.  The Terminal Oligo-Pyrimidine (TOP) motif is a regulatory element found almost 
exclusively in the 5’UTR of mRNAs encoding ribosomal subunits and components of the 
translational machinery. TOP motifs are bound by the RBP LARP1, which acts to suppress 
their translation.  LARP1 is phosphorylated by mTORC1 leading to its dissociation and 
enhanced translation of TOP containing transcripts62.  This provides a mechanism for 
mTOR signaling to coordinate increased global translation with increased ribosome 
biogenesis. Conversely, it provides a therapeutic opportunity to target RBPs and thereby 
translational activity, by inhibition of upstream signaling pathways such as mTOR. 
 
Musashi2 (MSI2) is an RBP and with a role in promoting both normal hematopoiesis and 
malignant transformation.  MSI2 is highly expressed in hematopoietic stem cells (HSCs) 
but its expression declines at subsequent stages of myeloid differentiation. Knockdown in 
mouse progenitors was associated with reduced HSC numbers. Conversely, forced 
expression of MSI2 was associated with increased proliferation of HSCs and impaired 
myeloid differentiation. Consistent with these effects MSI2 appears to play a pro-leukemic 
role in myeloid malignancies. Expression of MSI2 is increased in high risk MDS and AML 
where its increased expression correlates with poor prognosis63,64. It binds directly to 
mRNAs encoding key transcriptional regulators of myelopoiesis, Hoxa9, Myc and Ikzf2 and 
promotes their translation in a mouse model of AML. The expression of MSI2 is also 
increased in human CML blast crisis and is required for CML transformation65.  
Experiments in human CML cell lines and primary CML cells show that MSI2 binds the 
transcript encoding branched chain amino acid transaminase 1 (BCAT1) and promotes its 
translation. BCAT1, itself required for CML transformation, is an enzyme that catalyzes the 
production of valine, leucine and isoleucine and thus acts to enhance mTOR signaling and 
promote global translation initiation.  These experiments suggest a critical leukemia-
promoting role for MSI2 and potential as a therapeutic target.  This is supported by the 
description of a small molecule that inhibits MSI RNA interaction, which induced dose 
dependent toxicity to AML cells in vitro and in vivo66. 
 
A screen for MSI2 interacting partners that contribute to leukemogenesis in mice identified 
a second RBP, Syncrip (hnRNPQ1)67. Knockdown of Syncrip in mouse models of AML led 
to myeloid differentiation and apoptosis, whilst overexpression in a mouse AML cell line 
increased colony formation, enhanced cell growth and accelerated leukemogenesis in an 
in vivo model. Analysis of transcriptomes showed that Syncrip co-operated with MSI2 to 
enforce the hematopoietic stem cell and leukemia stem cell state.  Although not directly 
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interacting with MSI2, Syncrip binds overlapping mRNA targets of MSI2 including Myc, 
Hoxa9 and Ikzf2, and affects regulation predominantly at the level of translation. Although 
Syncrip is essential for maintenance of malignant tumor cells, Syncrip is not required for 
normal murine hematopoiesis. The apparent selective requirement for Syncrip in malignant 
hematopoiesis is intriguing and suggests a potential therapeutic opportunity. 
 
Whilst mechanisms that promote increased translation are generally associated with 
cellular transformation there are also examples where suppressed translation contributed 
to malignant disease. Translational profiling in CLL showed a translational downregulation 
of ribosome protein subunits and translational suppression of dyskeratin (DKC1) a protein 
required for rRNA processing and hence ribosome biogenesis.  Indeed, those patients with 
reduced levels of dyskeratin were associated with comparatively reduced overall survival 
after chemotherapy68.  These and other observations suggest that tumor cells have a 
“sweet spot” of optimal translation and that perturbations from this optimum might stress or 
kill tumor cells. 
 
mRNA Methylation 
Numerous chemical modifications to RNA have been described; however, the most 
prevalent and well-studied is N6-methyladenosine (m6A)69. RNA methylation influences 
RNA fate in many ways including effects on splicing, nuclear export, translation, and 
decay.  The m6A modification is mediated by two methyltransferases METTL3 and 
METTL14 and their cofactors WTAP, KIAA1429 and ZFP217.  The m6A modification can 
be removed by demethylases such as FTO and ALKBH5 (Figure 3A).  A further set of 
proteins bind m6A and regulate transcript stability and translation. METTL3 may promote 
translation through an interaction with EIF3H that promotes mRNA looping and ribosome 
recycling from the stop codon.  Disruption of this interaction suppresses the effect of 
METTL3 on translation and abolishes its ability to drive oncogenic transformation 70. 
 
Regulation of m6A has recently emerged as a regulator of normal and malignant 
hematopoiesis71,72.  METTL3 and METTL14 are both abundant in mouse and human 
hematopoietic stem cells and act to promote cell growth and repress differentiation.  These 
proteins are also highly expressed in AML and catalytically active METTL3 is required for 
maintenance of the malignant clone.  Loss of METTL3 led to loss of m6A and diminished 
translation of components of oncogenic pathways with an associated increased 
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expression of genes involved in hematopoietic differentiation (Figure 3B).  METTL3 also 
contributes to lymphoid homeostasis 73. When adoptively transferred to lymphopenic mice, 
Mettl3-deficient T cells were unable to expand or differentiate into effector cells yet 
persisted as naïve T cells. This reflected a reduced ability of T cells to respond to IL7 
signaling as a result of increased expression of the METTL3 target transcripts SOCS1, 
SOCS3 and CISH. Whilst m6A is the best studied RNA modification it is clear that very 
many other such modifications exist. How these modifications are imposed by protein 
effectors, how they influence RBP recruitment and their involvement in hematopoiesis and 
hematological malignancy is likely to be unraveled in coming years. 
 
mRNA Decay 
The cellular abundance of all RNA is determined by its rates of transcription and 
degradation.  RNA decay is regulated by RBPs that recognize and bind to cis-regulatory 
RNA elements and recruit mediators of decapping, deadenylation and exoribonucleolytic 
decay. A well-established element mediating decay is the AU rich element (ARE).  This is 
recognized by different RBPs including the ZFP36 and ELAV families of RBPs.  Mouse 
models provided the first evidence for the importance of these RBPs in the hematopoietic 
and immune systems. Zfp36l2 knockout mice showed depletion of hematopoietic stem cell 
and progenitor compartments and died within two weeks of birth from anemia and 
thrombocytopenia74.  The precise molecular mechanism was not established but Zfp36l2 
was proposed to balance HSC self-renewal with differentiation. Consistent with these 
findings, Zfp36l2 was shown to suppresses a program of transcripts promoting erythroid 
differentiation75.  ZFP36L2 expression is decreased from the BFU-E stage onwards 
allowing expression of transcripts promoting terminal differentiation. Interestingly, despite 
sharing almost identical zinc finger RNA interaction domains, germline knockouts of the 
two other family members, Zfp36 and Zfp36l1 show very different phenotypes.  A Zfp36 
knockout displayed a proinflammatory phenotype due to increased stability and 
overexpression of cytokines such as TNF, GMCSF and IL-23 whereas the Zfp36l1 
knockout had a lethal phenotype at embryonic day 9.576-78.  These findings demonstrate 
an unexpected degree of specificity between seemingly similar RBPs that may relate to 
tissue specific expression levels, tissue specific PTM, or the ability to recruit effector 
proteins. 
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More recently, conditional mutant mouse models have revealed roles of these proteins in 
hematopoiesis and the immune system. Simultaneous deletion of Zfp36l1 and Zfp36l2 in 
lymphocytes led to dysregulated B and T lymphopoiesis79.  In developing B cells double 
knockout resulted in a loss of quiescence prior to proper assembly and expression of the 
pre-BCR80.  RNA-Seq and individual-nucleotide resolution Cross-Linking and Immuno-
Precipitation (iCLIP) revealed co-ordination of transcripts that limit cell cycle progression.  
Loss of both Zfp36l1 and Zfp36l2 during thymopoiesis led to initial thymic atrophy 
associated with a loss of cell cycle control suggesting the existence of a conserved 
regulon of quiescence that is essential for correct antigen receptor gene rearrangement 
during lymphocyte development81.  As these double knockout mice aged further they 
developed T cell lymphoblastic leukemia, in part due to deregulated stability and 
expression of Notch1 mRNA79.   
 
The hypothesis that these genes might function as tumor suppressors in human 
malignancy was supported by a recent pan-cancer genomic analysis that identified 
evidence of strong selective pressure for inactivating mutation of ZFP36L1 and ZFP36L2 
across multiple tissue types, suggesting a conserved mechanism of tumor control82.  
Indeed, recent lymphoma sequencing studies have now identified recurrent inactivating 
mutations of ZFP36L183,84. A likely hypothesis is that these mutations act to promote cell 
cycle progression in tumor cells, however, recent observations suggest alternative 
mechanisms of tumor promotion.  Oncogenic RAS signaling in different cancer types led to 
increased expression of PDL1 on tumor cells, and hence suppression of the host anti-
tumor immune response85.  This effect was mediated by RAS-induced phosphorylation of 
ZFP36 which abolished its ability to bind and destabilize PDL1 mRNA. Indeed, oncogenic 
signaling activity of MAP kinase and PI3-kinase pathways may lead to global inactivation 
of ZFP36 proteins with downstream tumor promoting effects on both cell cycle control and 
immune interaction.  
 
Nonsense mediated decay (NMD) leads to the degradation of transcripts containing 
premature stop codons located prior to the final exon and those with especially long 
3’UTRs.  
A dominant mechanism promoting NMD is the accumulation of the RNA helicase UPF1 
downstream of the termination codon. RBPs including PTBP1 and hnRNPL are able to 
antagonize UPF1 accumulation by sequence-specific interaction with subsets of mRNAs. 
This mechanism is co-opted by lymphoma cells carrying the t(14:18) translocation 
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between BCL2 and the IgH locus. The resulting fusion transcript retains the BCL2 stop 
codon followed by several downstream IgH exons that would normally promote NMD and 
abrogate expression of BCL2 protein.  Instead, a CA rich element in the proximal 3’UTR 
recruits hnRNPL which protects the fusion transcript from NMD and permits expression of 
BCL2 protein86.  
Summary 
Our understanding of the multi-layered regulation imposed beyond the point of 
transcription is increasing.  Much of this regulation is mediated by RBPs, which allow 
coordinated remodeling of both the transcriptome and proteome in response to 
microenvironmental stimuli.  An emerging feature of many RBPs is their frequent 
involvement in different aspects of RNA metabolism. Thus, genetic or post-translational 
changes to an individual RBP may have consequences for many RNA targets but also at 
multiple points of their RNA metabolism.  An increased understanding of how RBPs 
influence this network of regulation in normal and malignant hematopoiesis is already 
revealing new strategies for therapeutic targeting.  These strategies may target the 
signaling pathways that control RBPs; the RBP itself; the RBP-RNA interaction; or the 
downstream alterations to the proteome mediated by changes in RBP function.  
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Figure legends 
 
Figure 1: SF3B1, SRSF2 and U2AF function in splicing   
(A) The U1 snRNP and U2AF initially bind to the 5” and 3” splice sites respectively. This is 
followed by binding of the SF3B-containing U2 snRNP and subsequently assembly of a 
multiprotein complex (including U4, U5 and U6 snRNPs) known as the “spliceosome”, 
which then leads to excision of the intervening intron. Further sequences within exons and 
introns act as splicing enhancer or silencer elements and are bound by proteins such as 
heterogeneous nuclear ribonucleoproteins (hnRNPs) and SR proteins (e.g. SRSF2). 
These RBPs allow splicing to be controlled in a tissue, developmental stage and stimulus 
specific manner. (B) SRSF2 binds equally to GGNG and CCNC exonic splicing enhancers 
(ESE) to allow expression of EZH2 in healthy hematopoietic stem/progenitor cells 
(HSPCs). In MDS/CMML the P95H mutation of SRSF2 has preferential binding CCNG 
ESE, giving rise to a splice variant of EZH2 including an exon with a premature stop codon 
that is degraded by nonsense mediated decay.  
 
Figure 2: Signaling to cap-dependent translation initiation 
Cap-dependent translation can be controlled through activation of the PI3K-mTOR and 
MAPK pathways. Binding of eIF4E and eIF4G is required for eIF4F function and 
translation of many mRNA, however, this can be inhibited by eIF4E-binding protein (4E-
BP). mTORC1 controls the binding of 4E-BP to eIF4E through phosphorylation of 4E-BP. 
Furthermore, mTORC1 can control the availability of eIF4A through activation of S6K1/2, 
which phosphorylates PDCD4 releasing eIF4A. Mitogen-activated protein kinase-
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interacting kinase 1/2 (MNK1/2), which is bound by eIF4G, can also regulate translation by 
phosphorylating eIF4E. The PI3K-mTOR and MAPK pathways converge to phosphorylate 
eIF4B, a cofactor of eIF4A, leading to increased eIF4A activity.   
 
Figure 3: m6A mRNA methylation control and dysregulation in AML 
(A) The amount of m6A mRNA methylation in a cell is determined by the activities of 
methyltransferases (METTL3 and METTL14) and demethylases (e.g. FTO and ALKBH5). 
(B) In healthy HSPCs knockout of METLL3 reduces methylation, increases differentiation 
and reduces cell growth whereas increased METTL3 has the opposite effect. AML cells 
frequently have increased METTL3 and increased methylation. In AML knockout of 
METTL3 leads to increased differentiation and apoptosis. 
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